Standout Papers

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell... 2021 2026 2022 2024230
  1. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer (2021)
    Jie Wang, Shun Lü et al. JAMA Oncology

Immediate Impact

4 from Science/Nature 63 standout
Sub-graph 1 of 23

Citing Papers

Selectivity in Chemiresistive Gas Sensors: Strategies and Challenges
2025 Standout
Changes in frailty and incident cardiovascular disease in three prospective cohorts
2024 Standout
2 intermediate papers

Works of Kejing Ying being referenced

Preserved Ratio Impaired Spirometry and COPD Accelerate Frailty Progression
2023
Different Risks of Mortality and Longitudinal Transition Trajectories in New Potential Subtypes of the Preserved Ratio Impaired Spirometry: Evidence From the English Longitudinal Study of Aging
2021
and 3 more

Author Peers

Author Last Decade Papers Cites
Kejing Ying 917 818 522 93 2.3k
Peter Lukáš 837 578 872 78 3.4k
York E. Miller 1613 1604 759 101 3.7k
Amir Onn 1278 954 1383 117 3.1k
Wolfgang Hilbe 766 1191 1273 129 3.8k
Stephen Lam 829 1167 561 83 2.3k
Paolo Carbognani 953 406 561 126 2.4k
Tsz‐Kwong Man 402 1537 895 124 3.8k
Sara Lindström 309 887 300 82 2.5k
Vathany Kulasingam 312 1330 482 93 2.8k
Yan Xu 350 1392 360 132 2.8k

All Works

Loading papers...

Rankless by CCL
2026